The latest jobs report showed a slowing pace of hiring which will affect stock market opportunities. The July jobs report showed slowing hiring with low unemployment.
Teladoc's solid position in telemedicine, improving bottom line, and strong margins make a solid case for the stock. Tandem Diabetes Care develops cutting-edge insulin pumps for diabetes patients, an
Wegovy and Mounjaro obesity and diabetes drugs are expected to have a significant impact on society and may lead to a decrease in demand for certain medical devices and surgeries. Medical device stock
Uncertainty from geopolitical tensions within the Ukraine war and China issues has led to slower United States labor market growth. In this environment of uncertainty, the United States labor market h
HCA Healthcare is a major player in an industry with no ceiling in sight. DexCom develops devices to help those with diabetes, a growing demographic.

5 Top Stocks Likely to Beat Earnings Estimates

08:11am, Wednesday, 02'nd Aug 2023
These top-ranked stocks are likely to beat on the bottom line in their upcoming releases. Tap Coty (COTY), BJ's Restaurants (BJRI), DexCom (DXCM), Livent (LTHM) and D.R.
Glucose-monitor maker DexCom Inc. NASDAQ: DXCM was among the top three gainers within the healthcare sector on July 28, advancing 2.33% in the season after gapping higher at the open.
Markets bounced back at midday on Friday, July 28, 2023 from yesterday's selloff and were heading for a winning week on the latest report showing inflation easing.
With a daily gain of 5.13%, DexCom Inc ( DXCM , Financial) has caught the attention of value investors. Its Earnings Per Share (EPS) (EPS) stands at 0.7.
DexCom's (DXCM) second-quarter 2023 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.

25 S&P 500 Stocks to Target Next Month

08:00am, Friday, 28'th Jul 2023
Subscribers to  Chart of the Week  received this commentary on Sunday, July 23.
Dexcom, Inc. (NASDAQ:DXCM ) Q2 2023 Earnings Conference Call July 27, 2023 4:30 PM ET Company Participants Sean Christensen - Director, Corporate Affairs & Head of IR Kevin Sayer - Executive Chairman,
DexCom (DXCM) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.17 per share a year ago.
Medical device maker Dexcom Inc on Thursday raised its annual revenue forecast after strong demand for its continuous glucose monitoring (CGM) systems boosted second-quarter results, lifting its share
On July 24, 2023, Steven Pacelli, the Executive Vice President and Managing Director of DexCom Inc ( DXCM , Financial), sold 412 shares of the company. This move is part of a broader trend of insider
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE